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293T  cells were  obtained  from  ATCC, Manassas,  VA, USA,  in  2011  and  confirmed  to  be 
mycoplasma negative by PCR  in October 2016. RT112 cell  lines were obtained from DSMZ, 
Braunschweig,  Germany,  in  2016.  RT112  wildtype,  RT112‐MRE11  KD,  RT112‐full  length 
MRE11 and RT112‐ MRE11  Δexon16  cells  (see below) were  confirmed  to be mycoplasma 





cm dishes  seeded at 5x106  cells per dish,  and 9 µg of either pLenti‐full  length MRE11 or 
pLenti‐MRE11‐Δexon16,  4.5  µg  of  psPAX2  (#12260;  Addgene, MA,  USA),  and  4.5  µg  of 
pMD2.G (#12259; Addgene, MA, USA) were delivered to each dish with Lipofectamine 3000 
 10
(Thermo  fisher, MA, USA)  in opti‐MEM  (Thermo  Fisher, Waltham, CA, USA),  according  to 
manufacturer’s  instructions.  The  generated  lentiviral  particles  were  collected  48  hr 
following  transfection and  filtered  through a 0.45 µm syringe  filter  (SLHV033RS; Millipore, 
Burlington, MA, USA). RT112‐MRE11 KD cells were generated as previously described [20], 
and additionally, a monoclonal cell  line was  isolated  from a polyclonal pool of stable cells 
and expanded. RT112‐MRE11 KD cells were infected with the filtered lentiviral supernatant 
using  8 µg/ml  of  polybrene. After  3  days  of  infection,  5 µg  of  puromycin was  added  for 
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Alignment of Sequences:  [Translation of  MRE11_Full length] with [Translation of  
MRE11 Δexon16]  
  
Similarity : 679/708 (95.90 %) 
  
MRE11 FL       MSTADALDDENTFKILVATDIHLGFMEKDAVRGNDTFVTLDEILRLAQENEVDFILLGGD  60 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  MSTADALDDENTFKILVATDIHLGFMEKDAVRGNDTFVTLDEILRLAQENEVDFILLGGD  60 
  
MRE11 FL       LFHENKPSRKTLHTCLELLRKYCMGDRPVQFEILSDQSVNFGFSKFPWVNYQDGNLNISI  120 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  LFHENKPSRKTLHTCLELLRKYCMGDRPVQFEILSDQSVNFGFSKFPWVNYQDGNLNISI  120 
  
MRE11 FL       PVFSIHGNHDDPTGADALCALDILSCAGFVNHFGRSMSVEKIDISPVLLQKGSTKIALYG  180 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  PVFSIHGNHDDPTGADALCALDILSCAGFVNHFGRSMSVEKIDISPVLLQKGSTKIALYG  180 
  
MRE11 FL       LGSIPDERLYRMFVNKKVTMLRPKEDENSWFNLFVIHQNRSKHGSTNFIPEQFLDDFIDL  240 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  LGSIPDERLYRMFVNKKVTMLRPKEDENSWFNLFVIHQNRSKHGSTNFIPEQFLDDFIDL  240 
  
MRE11 FL       VIWGHEHECKIAPTKNEQQLFYISQPGSSVVTSLSPGEAVKKHVGLLRIKGRKMNMHKIP  300 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  VIWGHEHECKIAPTKNEQQLFYISQPGSSVVTSLSPGEAVKKHVGLLRIKGRKMNMHKIP  300 
  
MRE11 FL       LHTVRQFFMEDIVLANHPDIFNPDNPKVTQAIQSFCLEKIEEMLENAERERLGNSHQPEK  360 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  LHTVRQFFMEDIVLANHPDIFNPDNPKVTQAIQSFCLEKIEEMLENAERERLGNSHQPEK  360 
  
MRE11 FL       PLVRLRVDYSGGFEPFSVLRFSQKFVDRVANPKDIIHFFRHREQKEKTGEEINFGKLITK  420 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  PLVRLRVDYSGGFEPFSVLRFSQKFVDRVANPKDIIHFFRHREQKEKTGEEINFGKLITK  420 
  
MRE11 FL       PSEGTTLRVEDLVKQYFQTAEKNVQLSLLTERGMGEAVQEFVDKEEKDAIEELVKYQLEK  480 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  PSEGTTLRVEDLVKQYFQTAEKNVQLSLLTERGMGEAVQEFVDKEEKDAIEELVKYQLEK  480 
  
MRE11 FL       TQRFLKERHIDALEDKIDEEVRRFRETRQKNTNEEDDEVREAMTRARALRSQSEESASAF  540 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  TQRFLKERHIDALEDKIDEEVRRFRETRQKNTNEEDDEVREAMTRARALRSQSEESASAF  540 
  
MRE11 FL       SADDLMSIDLAEQMANDSDDSISAATNKGRGRGRGRRGGRGQNSASRGGSQRGRADTGLE  600 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||###### 
MRE11 Δexon16  SADDLMSIDLAEQMANDSDDSISAATNKGRGRGRGRRGGRGQNSASRGGSQRGR------  594 
  
MRE11 FL       TSTRSRNSKTAVSASRNMSIIDAFKSTRQQPSRNVTTKNYSEVIEVDESDVEEDIFPTTS  660 
               #######################||||||||||||||||||||||||||||||||||||| 
MRE11 Δexon16  -----------------------FKSTRQQPSRNVTTKNYSEVIEVDESDVEEDIFPTTS  631 
  
MRE11 FL       KTDQRWSSTSSSKIMSQSQVSKGVDFESSEDDDDDPFMNTSSLRRNRR  708 
               |||||||||||||||||||||||||||||||||||||||||||||||| 


















ENST00000393241.8 ENST00000323929.7 (isoform 1) ENST00000407439.7 ENST00000540013.5 ENST00000323977.7 (isoform 2)
ENST00000393241.8 0.8377458 0.4212147 0.02399145 0.9987925
ENST00000323929.7 (Isoform 1) 0.1625645 0.2043732 0.001220884 0.9825811
ENST00000407439.7 0.5793591 0.7960142 0.0238522 0.9994933
ENST00000540013.5 0.9761061 0.9987856 0.9762505 0.9999999
ENST00000323977.7 (Isoform 2) 0.001212826 0.01747047 0.00050929 1.45E‐07
ENST00000323977.7 (Isoform 2), P‐values 
corrected (Holm–Bonferroni) 0.001617101 0.01747047 0.00101858 0.00000058
Variant vs. Wild‐type expression  of individulal 
isoforms. The expression‐ratios of blue to 
green have been tested between variant and 
WT (Wilcoxon test on increased expression of 
'blue', one sided, unpaired) and P‐values are 
Isoforms which are expressed in less of 70% of 
samples have been discarded, and samples 
with no expression for an isoform of the 
comparison have been skipped.
Yellow: P‐value < 0.05
Corrected P‐values given for the analysis  

















fraction of samples 
in which the 
isoform is 
expressed





p‐values, for 'isoform 
has higher 
expression in GA,AA 
compared to GG', 
corrected for multiple 
testing with 
p‐value for 'isoform 
has lower expression 
in GA,AA compared to 
GG'




to GG', corrected 
with 
Isoform 1 ENST00000323929.7|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396237.4|MRE11‐201|MRE11|6897|protein_coding| yes 6897 708 4546 222 1 0.3779377 0.999539 0.6224927 0.691658556
ENST00000407439.7|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396234.1|MRE11‐204|MRE11|2684|protein_coding| yes 2684 711 258 288 0.9 0.9872987 0.999539 0.01273852 0.049932267
Isoform 2 ENST00000323977.7|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396235.2|MRE11‐202|MRE11|2588|protein_coding| no 2588 680 248 295 0.956097561 4.84E‐05 0.000484 0.9999519 0.9999519
ENST00000393241.8|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396236.1|MRE11‐203|MRE11|2604|protein_coding| yes 2604 707 246 232 0.931707317 0.8567794 0.999539 0.1434768 0.239128
ENST00000535120.1|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396251.1|MRE11‐205|MRE11|234|retained_intron| yes 234 ‐ ‐ ‐ 0.017073171 0.8845519 0.999539 0.1164288 0.2328576
ENST00000540013.5|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396239.1|MRE11‐209|MRE11|1212|protein_coding| no 1212 221 396 148 0.809756098 0.999539 0.999539 0.000462844 0.00462844
ENST00000541157.5|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396252.1|MRE11‐210|MRE11|594|processed_transcript| no 594 ‐ ‐ ‐ 0.073170732 0.9312637 0.999539 0.06907281 0.172682025
ENST00000536754.5|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396241.3|MRE11‐207|MRE11|572|protein_coding| no 572 127 ‐ 190 0.204878049 0.9850816 0.999539 0.01497968 0.049932267
ENST00000538923.1|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396253.2|MRE11‐208|MRE11|558|protein_coding| no 558 111 ‐ 224 0.070731707 0.6452692 0.999539 0.3556909 0.508129857
ENST00000536144.1|ENSG00000020922.12|OTTHUMG00000167780.6|OTTHUMT00000396254.1|MRE11‐206|MRE11|619|processed_transcript| no 619 ‐ ‐ ‐ 0.163414634 0.5841205 0.999539 0.4165673 0.520709125
Overview on isoforms used 
in the TCGA analysis, based 
on Gencode 29/30
P‐values computed using 
Wilcoxon one sided unpaired 
test on fractions of isoform 
expression against all others 





#NCBI Reference SNP (rs) Report ALPHA rs1805363
#Current Build 152
#Released October 12, 2018
#Organism Homo sapiens
#Position chr11:94493786 (GRCh38.p12)
#Alleles C>A / C>G / C>T





#Study Population Group Sample size Ref Allele Alt Allele BioProject ID BioSample ID
TopMed Global Study‐wide 125568 C=0.94456
T=0.05542, 
G=0.00002 PRJNA400167
gnomAD ‐ Genomes Global Study‐wide 30958 C=0.9395 T=0.0605 PRJNA398795 SAMN07488253
gnomAD ‐ Genomes European Sub 18492 C=0.9134 T=0.0866
gnomAD ‐ Genomes African Sub 8728 C=0.982 T=0.018 SAMN07488254
gnomAD ‐ Genomes East Asian Sub 1622 C=1.000 T=0.000 SAMN07488251
gnomAD ‐ Genomes Other Sub 978 C=0.93 T=0.07 SAMN07488248
gnomAD ‐ Genomes American Sub 836 C=0.96 T=0.04 SAMN07488255
gnomAD ‐ Genomes Ashkenazi Jewish Sub 302 C=0.96 T=0.04 SAMN07488252
1000Genomes Global Study‐wide 5008 C=0.973 T=0.027 PRJEB6930 SAMN07490465
1000Genomes African Sub 1322 C=0.995 T=0.005 SAMN07486022
1000Genomes East Asian Sub 1008 C=0.999 T=0.001 SAMN07486024
1000Genomes Europe Sub 1006 C=0.917 T=0.083 SAMN07488239
1000Genomes South Asian Sub 978 C=0.99 T=0.01 SAMN07486027
1000Genomes American Sub 694 C=0.95 T=0.05 SAMN07488242
Genetic variation in the Estonian 
population Estonian Study‐wide 4480 C=0.922 T=0.078 PRJNA489787
The Avon Longitudinal Study of Parents 
and Children
PARENT AND CHILD 
COHORT Study‐wide 3854 C=0.901 T=0.099 PRJEB7217
UK 10K study ‐ Twins TWIN COHORT Study‐wide 3708 C=0.902 T=0.098 PRJEB7218
